Participant flow

Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants · Source last updated 2017-03-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   bortezomib in combination with high-dose melphalan as a conditioning regimen for autologous peripheral blood stem cell transplant Bortezomib : the maximum tolerated dose (MTD) of bortezomib in combination with high-dose melphalan as a conditioning regimen for autologous stem cell transplant PBSCT : PBSCT #1 Day 0 PBSCT #2 Day 0 (approx 90 days =/- 15 days after PBSCT #1) Melphalan : Day -4 melphalan 100 mg/m2 intravenously over 30 minutes, Day -3 melphalan 100 mg/m2 intravenously over 30 minutes

   id

   FG000

   title

   Autologous PBSCT

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         5

      type

      ineligible

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         30

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         25

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         5

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

Participants recruited from the Blood and Marrow Transplant (BMT) program at H. Lee Moffitt Cancer Center.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice